Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Prasugrel: Phase III data

In the double-blind, international Phase III TRITON TIMI-38 trial in 13,608 patients, prasugrel met the primary endpoint of a reduction in the composite

Read the full 234 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE